Below is the drafted patent application following the provided outline and research paper content. The application is structured according to the outline's headings and subheadings, with each section containing detailed descriptions as required for a formal patent application.  

---

# **DESCRIPTION**  

## **BACKGROUND**  

Synthetic lethality (SL) is a phenomenon wherein the simultaneous inactivation of two nonessential genes results in cellular inviability, while the inactivation of either gene alone does not. This concept, originally studied in yeast, has significant implications in human therapeutics, particularly in cancer treatment, where targeting SL pairs can selectively kill cancer cells while sparing healthy tissue. However, the experimental identification of SL interactions in humans is prohibitively expensive and ethically challenging, requiring over 200 million assays to evaluate all possible gene pairs in a single cellular context.  

Existing computational methods for predicting SL rely primarily on genetic homology, assuming that orthologous gene pairs maintain SL relationships across species. However, this approach is limited by the small fraction of human genes with identifiable homologs (~2,000 genes), leaving the majority of potential SL pairs unexplored. Additionally, evolutionary divergence introduces functional redundancies that disrupt SL conservation, further reducing the predictive power of homology-based methods.  

To overcome these limitations, the present invention introduces a novel computational framework that leverages **connectivity homology**—a measure of similarity in network interaction patterns—to predict SL relationships across species without relying on genetic or functional similarity. This method significantly outperforms prior approaches, enabling high-confidence SL predictions in humans and other species with available protein-protein interaction (PPI) networks.  

---

## **SUMMARY**  

The present invention provides a computational method, **Species-INdependent TRAnslation (SINaTRA)**, for identifying synthetic lethal (SL) gene pairs in any species with an available PPI network. The method comprises the following key steps:  

1. **Introducing a synthetic lethality identification method** based on connectivity homology, wherein SL relationships are inferred from network interaction patterns rather than genetic or functional similarity.  
2. **Describing a biological network model framework** that represents genes and their interactions as nodes and edges in a PPI network.  
3. **Outlining a method for predicting synthetic lethality** by training a machine learning model on SL data from a well-characterized source species (e.g., *S. cerevisiae*) and applying it to a target species (e.g., humans).  
4. **Detailing normalization of network parameters** to enable cross-species comparison, including rank normalization to rescale parameter values between 0 and 1.  
5. **Training a species-independent synthetic lethality model** using random forest classifiers to distinguish SL from non-SL pairs based on connectivity profiles.  
6. **Outlining a method for selecting cancer drug treatments** by identifying high-confidence SL pairs that can be targeted for combination therapy.  
7. **Describing filtering of synthetic lethality pairs** to remove false positives using population genetic variation data.  

The invention further provides databases of predicted SL pairs and methods for applying these predictions to therapeutic development, particularly in oncology.  

---

## **DETAILED DESCRIPTION**  

### **Method for Identifying Synthetic Lethality**  

The disclosed method involves training a predictive model on experimentally validated SL pairs from a source species (e.g., *S. cerevisiae*) and applying it to a target species (e.g., humans) using PPI network data. The model evaluates **connectivity homology**, wherein genes with similar interaction patterns are more likely to exhibit SL relationships.  

### **Use of Biological Network Connectivity Profiles**  

Each gene pair is represented by a **connectivity profile**, a vector of network parameters including:  
- Degree centrality  
- Betweenness centrality  
- Shortest path distance  
- Communicability  
- Shared neighbors  

These parameters are computed from PPI networks constructed using data from BioGRID or similar databases.  

### **Translation of Parameters for Comparison**  

Due to differences in network scale and topology across species, raw parameter values are not directly comparable. The invention employs **rank normalization**, wherein parameter values are rescaled to a uniform range (0–1) based on their relative ranks within each species.  

### **Constructing the Model on a Source Species**  

A random forest classifier is trained on *S. cerevisiae* SL data, using connectivity profiles as features. The model achieves high predictive accuracy (AUC = 0.92) in cross-validation.  

### **Applying the Model to a Target Species**  

The trained model is applied to normalized PPI networks of target species (e.g., *S. pombe*, *M. musculus*, humans) to generate **SINaTRA scores** (0–1) for each gene pair, indicating SL likelihood.  

### **Predicting SL Pairs in the Target Species**  

High-scoring pairs (e.g., SINaTRA ≥ 0.85) are prioritized for experimental validation. The method outperforms homology-based approaches (AUC = 0.86 vs. 0.60).  

### **Generating Biological Networks**  

PPI networks are pruned to ensure a single connected component, improving computational efficiency.  

### **Describing Network Parameters**  

Key parameters include:  
- **Node-level**: Degree, clustering coefficient  
- **Pair-level**: Inverse shortest path, shared neighbors  

### **Normalizing Network Parameters**  

Four normalization strategies were evaluated, with **rank normalization** selected for optimal cross-species performance.  

### **Training a Species-Independent Model**  

The random forest model is robust to network incompleteness, maintaining high accuracy even with 50% edge ablation.  

### **Applying the Model to Normalized Target Networks**  

The model is applied to human PPI networks, generating SL predictions for ~110 million gene pairs.  

### **Predicting SL Pairs**  

High-confidence predictions are filtered to remove false positives using co-mutation data from population genomics studies.  

### **Choosing Source Species Based on Known SL Information**  

*S. cerevisiae* is selected as the primary source due to its extensive SL annotation.  

### **Defining Connectivity Homologous Relationships**  

Two genes are **connectivity homologous** if their network interaction patterns are similar, regardless of genetic or functional similarity.  

### **Representing Connectivity Profiles as Vectors**  

Each gene pair is encoded as a 20-dimensional vector combining individual and pairwise network parameters.  

### **Determining Network Parameters**  

Graph-theoretic metrics are computed using NetworkX, with additional custom metrics for shared neighbors.  

### **Pruning Networks to Contain One Connected Component**  

Disconnected subnetworks are excluded to ensure consistent parameter calculation.  

### **Normalizing Network Parameters**  

Rank normalization ensures comparability across species with differing network densities.  

### **Performing Entropy Analysis**  

Parameter distributions are analyzed to confirm normalization efficacy.  

### **Training Models of Synthetic Lethality**  

Random forest classifiers are trained on SL/NSL labels, with feature importance analysis.  

### **Selecting SL and NSL Pairs**  

Positive examples are experimentally validated SL pairs; negative examples are randomly selected non-SL pairs.  

### **Evaluating Model Performance**  

Performance is assessed via AUC, precision-recall curves, and odds ratios.  

---

### **EXAMPLE 1**  

#### **Predicting SL in *S. pombe***  

The model trained on *S. cerevisiae* was applied to *S. pombe*, achieving an AUC of 0.86 with rank-normalized parameters, compared to 0.67 without normalization. High-scoring pairs (SINaTRA ≥ 0.85) had a 70-fold enrichment for true SL interactions.  

#### **Comparing Untranslated and Normalized Parameters**  

Untranslated parameters yielded poor cross-species prediction (AUC = 0.60), while normalized parameters significantly improved accuracy.  

#### **Evaluating Model Performance**  

The model identified 177 expected SL pairs in *S. pombe*, of which only 65 had been experimentally confirmed, suggesting many novel SL interactions.  

---

### **EXAMPLE 2**  

#### **Predicting SL in *M. musculus***  

The model predicted SL in mice with high accuracy (AUC = 0.937), outperforming functional similarity (AUC = 0.687). Five of nine known mouse SL pairs were correctly predicted with scores ≥ 0.70.  

---

### **EXAMPLE 3**  

#### **Applying the SL Model to Human Network Parameters**  

The model generated SINaTRA scores for all human gene pairs, with high-confidence predictions (≥ 0.95) enriched for known SL pairs.  

#### **Generating a Score for Human Gene Pairs**  

Scores were filtered using co-mutation data to remove likely false positives (FDR = 0.36%).  

#### **Compiling a Database of Severe, Tolerated, and Deleterious Co-Mutations**  

Pairs with homozygous deleterious mutations in both genes were excluded as non-SL.  

#### **Evaluating All Gene Pairs**  

450,010 pairs were filtered out, improving prediction specificity.  

#### **Filtering False Positives**  

High-scoring pairs (≥ 0.95) were retained for therapeutic exploration.  

#### **Determining False Discovery Rate**  

The FDR was 0.36% at a SINaTRA cutoff of 0.85.  

#### **Showing Putative SL Pairs in the Same Pathway**  

KEGG pathway analysis confirmed enrichment for intra-pathway SL pairs (p < 2.2e-16).  

#### **Analyzing Protein Complexes**  

Within-complex pairs had significantly higher SINaTRA scores (p < 0.0001).  

#### **Plotting Scores of Associated Genes**  

Heatmaps revealed clusters of high-scoring pairs corresponding to known drug targets.  

#### **Showing Enrichment for Higher Scores**  

Drug-targeted gene pairs had median SINaTRA scores 2–3× higher than non-targeted pairs.  

#### **Exploring Context-Specific SL Pairs**  

Tissue-specific filtering identified SL pairs relevant to cancer subtypes.  

#### **Comparing SL Predictions with Syn-Lethality and DAISY Databases**  

SINaTRA scores were significantly higher for known SL pairs (p < 2.2e-16).  

#### **Selecting SL Gene Pairs Involving Genetic Deficiency**  

34 of 88 Syn-Lethality pairs were correctly predicted (p = 4.8e-11).  

#### **Predicting Genes Present in Both DAISY and Syn-Lethality Datasets**  

SINaTRA achieved AUCs of 0.73 and 0.93, respectively.  

#### **Analyzing the Landscape of Human Synthetic Lethality**  

Pathway analysis revealed 73% of SL pairs were intra-pathway, with immune system genes highly interconnected.  

#### **Categorizing Predicted SL Pairs Using Biological Pathway Data**  

Reactome annotations identified functional clusters of SL pairs.  

#### **Presenting a Network Diagram of SL Pairs**  

Cytoscape visualization highlighted pathway-specific SL interactions.  

#### **Analyzing Function-Specific Mechanisms of Synthetic Lethality**  

Parallel pathway SL pairs were enriched in signal transduction, while complex-based SL dominated DNA repair.  

#### **Annotating Putative SL Gene Pairs for Mechanisms**  

56% of high-confidence pairs involved protein complexes.  

#### **Identifying Enrichments for Particular Mechanisms of SL**  

Immune system SL pairs were enriched for parallel pathways (OR = 1.48).  

#### **Identifying Novel Cancer Therapies Using Putative SL Pairs**  

High-scoring pairs overlapped with known cancer drug targets, suggesting new combination therapies.  

#### **Illustrating Application in Cancer Treatment**  

Hotspots of high SINaTRA scores corresponded to clinical-stage drug combinations, validating predictive utility.  

---

This concludes the detailed description of the invention. The disclosed method enables high-confidence prediction of synthetic lethality across species, with significant applications in drug discovery and personalized medicine.  

**END OF DESCRIPTION**